GIP, human


  • Description

  • Application Data


Gastric inhibitory peptide (GIP) is a member of the secretin hormone family and plays an important role in the regulation of plasma glucose and insulin secretion.

See full description

Application Data

Catalogue number crb1000991
Molecular Weight 4980.5
Sequence (one letter code)


Sequence (three letter code)


Aliase Gastric inhibitory peptide
Purity >95%
cas 100040-31-1
Storage -20°C

Skrha et al (2010) Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients. Physiol. Res. 59(5) 749 PMID: 20406045

Yamada and Seino (2004) Physiology of GIP–a lesson from GIP receptor knockout mice. Horm. Metab. Res. 36 (11–12) 771 PMID: 15655707

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Gastric inhibitory polypeptide (GIP) is an inhibiting hormone of the secretin family of hormones. While GIP is a weak inhibitor of gastric acid secretion, its main role is to stimulate insulin secretion – in a glucose-dependent mechanism. Therefore, GIP is referred to as a glucose-dependent insulinotropic peptide.

GIP is derived from a 153-amino acid pro-protein encoded by the GIP gene and circulates as a biologically active 42-amino acid peptide. It is synthesised by K cells, which are found in the mucosa of the duodenum and the jejunum of the gastrointestinal tract. GIP receptors are seven-transmembrane proteins found on beta-cells in the pancreas. These beta-cells are those that are able to simultaneously detect glucose and release insulin as a result to GIP binding.

The clinical relevance of GIP is related to type 2 diabetes mellitus (T2DM); studies have found that T2DM diabetics are unresponsive to GIP and have lower levels of GIP secretion after a meal when compared to non-diabetics. In research involving knockout mice, it was found that absence of the GIP receptors correlates with resistance to obesity.

GIP, human

Cat No.Pack SizePriceQty.
Bulk Quote